Forward and reverse mutations in stages of cancer development

BackgroundMassive occurrences of interstitial loss of heterozygosity (LOH) likely resulting from gene conversions were found by us in different cancers as a type of single-nucleotide variations (SNVs), comparable in abundance to the commonly investigated gain of heterozygosity (GOH) type of SNVs, raising the question of the relationships between these two opposing types of cancer mutations.MethodsIn the present study, SNVs in 12 tetra sample and 17 trio sample sets from four cancer types along with copy number variations (CNVs) were analyzed by AluScan sequencing, comparing tumor with white blood cells as well as tissues vicinal to the tumor. Four published “nontumor”-tumor metastasis trios and 246 pan-cancer pairs analyzed by whole-genome sequencing (WGS) and 67 trios by whole-exome sequencing (WES) were also examined.ResultsWidespread GOHs enriched with CG-to-TG changes and associated with nearby CNVs and LOHs enriched with TG-to-CG changes were observed. Occurrences of GOH were 1.9-fold higher than LOH in “nontumor” tissues more than 2 cm away from the tumors, and a majority of these GOHs and LOHs were reversed in “paratumor” tissues within 2 cm of the tumors, forming forward-reverse mutation cycles where the revertant LOHs displayed strong lineage effects that pointed to a sequential instead of parallel development from “nontumor” to “paratumor” and onto tumor cells, which was also supported by the relative frequencies of 26 distinct classes of CNVs between these three types of cell populations.ConclusionsThese findings suggest that developing cancer cells undergo sequential changes that enable the “nontumor” cells to acquire a wide range of forward mutations including ones that are essential for oncogenicity, followed by revertant mutations in the “paratumor” cells to avoid growth retardation by excessive mutation load. Such utilization of forward-reverse mutation cycles as an adaptive mechanism was also observed in cultured HeLa cells upon successive replatings. An understanding of forward-reverse mutation cycles in cancer development could provide a genomic basis for improved early diagnosis, staging, and treatment of cancers.

[1]  Li-Wei Zhang,et al.  Copy number variation analysis based on AluScan sequences , 2014, Journal of Clinical Bioinformatics.

[2]  Y. Tu,et al.  Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis , 2013, Molecular and Cellular Biochemistry.

[3]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[4]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[5]  T. Schlott,et al.  High frequency of promoter methylation of the 14-3-3 sigma and CAGE-1 genes, but lack of hypermethylation of the caveolin-1 gene, in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder. , 2007, International journal of molecular medicine.

[6]  H. Vasen,et al.  Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations , 2007, BMC Medical Genetics.

[7]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[8]  Manuel Ruiz-Rubio,et al.  Comparison of a forward and a reverse mutation assay in Salmonella typhimurium measuring L‐arabinose resistance and histidine prototrophy. , 1984, EMBO Journal.

[9]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[10]  Martin A. Nowak,et al.  Genetic Progression and the Waiting Time to Cancer , 2007, PLoS Comput. Biol..

[11]  B. Reid,et al.  Limitations of the Driver/Passenger Model in Cancer Prevention , 2016, Cancer Prevention Research.

[12]  W. Bodmer,et al.  Genetic pathways in colorectal and other cancers. , 1999, European journal of cancer.

[13]  Arthur P. Grollman,et al.  Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing , 2016, Proceedings of the National Academy of Sciences.

[14]  M. Roncalli,et al.  Abnormal DNA content in liver‐cell dysplasia: A flow cytometric study , 1989, International journal of cancer.

[15]  Robert T. Jones,et al.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.

[16]  E. Zhou,et al.  Intratumoral CD8+ Cytotoxic Lymphocyte Is a Favorable Prognostic Marker in Node-Negative Breast Cancer , 2014, PloS one.

[17]  J. Toretsky,et al.  Factor VII deficiency and developmental abnormalities in a patient with partial monosomy of 13q and trisomy of 16p: case report and review of the literature , 2006, BMC Medical Genetics.

[18]  Serena Nik-Zainal,et al.  Mechanisms underlying mutational signatures in human cancers , 2014, Nature Reviews Genetics.

[19]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[20]  Hua-xian Zhang,et al.  Detection of HBV, PCNA and GST-pi in hepatocellular carcinoma and chronic liver diseases. , 2003, World journal of gastroenterology.

[21]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[22]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[23]  Andrew Menzies,et al.  Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue , 2015, Nature Genetics.

[24]  B. Sjöberg,et al.  Confounded cytosine! Tinkering and the evolution of DNA , 2001, Nature Reviews Molecular Cell Biology.

[25]  Dimitris Kletsas,et al.  Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions , 2005, Nature.

[26]  M. Greaves,et al.  Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. , 2010, Blood.

[27]  M. Tang,et al.  Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair , 2006, Proceedings of the National Academy of Sciences.

[28]  L. Looijenga,et al.  Testicular germ-cell tumours in a broader perspective , 2005, Nature Reviews Cancer.

[29]  Lingling Mei,et al.  AluScan: a method for genome-wide scanning of sequence and structure variations in the human genome , 2011, BMC Genomics.

[30]  Michael O Dorschner,et al.  Sequencing newly replicated DNA reveals widespread plasticity in human replication timing , 2009, Proceedings of the National Academy of Sciences.

[31]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[32]  E. Birney,et al.  Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt , 2009, Nature Protocols.

[33]  M. Lieb.  Forward and Reverse Mutation in a Histidine-Requiring Strain of Escherichia Coli. , 1951, Genetics.

[34]  T. Skopek,et al.  Relative sensitivities of forward and reverse mutation assays in Salmonella typhimurium. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[36]  Subhajyoti De,et al.  The landscape of somatic mutations in protein coding genes in apparently benign human tissues carries signatures of relaxed purifying selection , 2016, Nucleic acids research.

[37]  Meng-wei Wang,et al.  A novel gene, GCRG224, is differentially expressed in human gastric mucosa. , 2003, World journal of gastroenterology.

[38]  Julian Gehring,et al.  SomaticSignatures: inferring mutational signatures from single-nucleotide variants , 2014, bioRxiv.

[39]  F. Watt,et al.  FRMD4A upregulation in human squamous cell carcinoma promotes tumor growth and metastasis and is associated with poor prognosis. , 2012, Cancer research.

[40]  Yujian Shi,et al.  Whole-genome sequencing of matched primary and metastatic hepatocellular carcinomas , 2014, BMC Medical Genomics.

[41]  N. Tretyakova,et al.  Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers , 2002, Oncogene.

[42]  Peng Zhang,et al.  Massive interstitial copy-neutral loss-of-heterozygosity as evidence for cancer being a disease of the DNA-damage response , 2015, BMC Medical Genomics.

[43]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[44]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[45]  A. Long,et al.  Experimental evolution reveals natural selection on standing genetic variation , 2009, Nature Genetics.

[46]  H. Rubin,et al.  Heritable, population-wide damage to cells as the driving force of neoplastic transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[48]  Lei Bao,et al.  AbsCN-seq: a statistical method to estimate tumor purity, ploidy and absolute copy numbers from next-generation sequencing data , 2014, Bioinform..

[49]  Hanlee P. Ji,et al.  Pan-cancer analysis of the extent and consequences of intratumor heterogeneity , 2015, Nature Medicine.

[50]  H. Xue,et al.  Feature co-localization landscape of the human genome , 2016, Scientific Reports.

[51]  H. Xue,et al.  Variation of global DNA methylation levels with age and in autistic children , 2016, Human Genomics.

[52]  T. Roskams,et al.  The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. , 2000 .

[53]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.